New Covid Strategies
The FDA has recently approved (emergency use authorization) two oral antivirals and a monoclonal antibody for Covid. The antivirals are designed for out patient use in mild to moderate Covid-19. Both have proven to be active against the original Corona virus and its new variants. Paxlovid uses two agents: nirmatrelvir (a viral protease inhibitor) and ritonavir (a CYP3a inhibitor). The treatment is for 5 days and can be used down to the age of 12. Lagevrio contains molnupiravir a nucleoside…